Adolor Corp (ADLR) SEC Filing 10-K Annual report for the fiscal year ending Friday, December 31, 2010

Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact:

Adolor Corporation

Stephen W. Webster

Senior Vice President, Finance and CFO

(484) 595-1500

ADOLOR REPORTS YEAR-END 2010 RESULTS

— ENTEREG® Net Sales Increase 74% in 2010 over 2009 —

— Phase 2 Clinical Evaluation of ADL5945 in OIC Underway —

EXTON, PA, February 23, 2010 — Adolor Corporation (NasdaqGM: ADLR) today reported a net loss of $27.3 million, or $(0.59) per basic and diluted share, for the year ended December 31, 2010, compared to a net loss of $47.9 million, or $(1.03) per basic and diluted share, for the year ended December 31, 2009.

“2010 was a year of continued progress for Adolor,” said Michael R. Dougherty, President and Chief Executive Officer.  “The year was highlighted by the advancement of our OIC program with the initiation of Phase 2 clinical evaluation of ADL5945.”  Mr. Dougherty continued, “In 2010, we also saw steady growth in ENTEREG sales and reductions in our cash burn from operations.  We look forward to continued growth for ENTEREG and to completing our Phase 2 OIC trials in the third quarter of this year.”

Operating Highlights

Net product sales of ENTEREG for the year ended December 31, 2010 were $25.4 million compared to $14.6 million for the year ended December 31, 2009, primarily driven by an increase in the number of ordering hospitals and increased penetration within existing hospital customers.  Net product sales of ENTEREG were $7.3 million for the three months ended December 31, 2010; for the same period in 2009, net product sales were $7.5 million, which included $2.6 million of product shipped to hospitals prior to that quarter, but not recognized as revenue at the time of shipment under the Company’s previous revenue recognition policy.  Effective as of the beginning of the fourth quarter of 2009, the Company began to recognize net product sales upon the shipment of ENTEREG to the hospital.  Net sales of ENTEREG for the fourth quarter of 2010 increased 12% over the third quarter of 2010.

Contract revenues were $17.9 million and $22.8 million for the years ended December 31, 2010 and 2009, respectively, and $3.7 million and $5.5 million for the three months ended December 31, 2010 and 2009, respectively.  The decreases in 2010 were driven primarily by reduced reimbursements under our GSK and Pfizer collaboration agreements.